Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
221
-
Total 13F shares, excl. options
-
128M
-
Shares change
-
+1.26M
-
Total reported value, excl. options
-
$2.61B
-
Value change
-
+$19.5M
-
Put/Call ratio
-
0.58
-
Number of buys
-
112
-
Number of sells
-
-92
-
Price
-
$20.38
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q4 2024
260 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q4 2024.
Denali Therapeutics Inc. - Common Stock (DNLI) has 221 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 128M shares
of 145M outstanding shares and own 88.07% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (13.9M shares), BAILLIE GIFFORD & CO (12.3M shares), VANGUARD GROUP INC (12M shares), WELLINGTON MANAGEMENT GROUP LLP (9.85M shares), FMR LLC (8.02M shares), Capital Research Global Investors (5.48M shares), Temasek Holdings (Private) Ltd (5.36M shares), STATE STREET CORP (4.54M shares), Crestline Management, LP (4.31M shares), and BAKER BROS. ADVISORS LP (3.73M shares).
This table shows the top 221 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.